CTLA4 and neoplasm: In patients with cancer, tumors often control immune checkpoints (such as CTLA-4 or PD-1/PD-L1) to cause T cell dysfunction or inhibition which blocks the host anti-tumor immune response to protect tumor tissue (Binnewies et al., 2018; Taube et al., 2018; Jia et al., 2020).